关节假体周围感染病原菌及其药敏特征分析

Pathogens in periprosthetic joint infection and their antimicrobial susceptibility profiles

  • 摘要: 背景 假体周围感染(periprosthetic joint infection,PJI)是关节置换术后灾难性的并发症。受限于细菌培养的时效性,临床早期常需依赖经验性抗菌治疗。由于病原菌分布及耐药特征具有明显的地域和机构差异,仅凭其他中心的数据难以指导本机构的精准用药。目的 分析解放军总医院关节假体周围感染关节液培养阳性病例的病原学分布与经验性治疗常用抗菌药物的耐药特征。方法 回顾性纳入解放军总医院2015 年5 月至2023 年12 月髋/膝PJI 患者,统计总体及髋、膝分层的病原菌构成比,分析主要抗菌药物耐药率并比较常用经验性抗菌方案的总体覆盖率、总体敏感率和总体有效覆盖率。结果 共纳入PJI 患者214 例,平均年龄为(62.8±13.1)岁;女性109 例(50.9%),男性105 例(49.1%);髋关节101 例(47.2%),膝关节113 例(52.8%)。共获得关节液培养阳性记录225 条。致病菌中革兰阳性菌180 株(80%),革兰氏阴性菌27 株(12.0%),真菌16 株(7.1%)。革兰氏阳性菌以表皮葡萄球菌79 株(35.1%),金黄色葡萄球菌32 株(14.2%)为主;革兰氏阴性菌中大肠埃希菌最为常见(9 株,4.0%),铜绿假单胞菌7 株(3.1%)为主;真菌16 株(7.1%)主要是近平滑念珠菌8 株(3.6%)和白色念珠菌3 株(1.3%)。膝关节118 株,最常见的病原菌为表皮葡萄球菌36 株(30.5%),金黄色葡萄球菌19 株(16.1%)和近平滑念珠菌8 株(6.8%);髋关节107 株,以表皮葡萄球菌43 株(40.2%),金黄色葡萄球菌13 株(12.1%)和大肠埃希菌8 株(7.5%)为主。膝关节真菌比例高于髋关节(12.7% vs 0.9%,P<001);大肠埃希菌在髋关节的比例高于膝关节(7.5% vs 0.8%,P=015)。主要抗菌药物耐药显示:金黄色葡萄球菌与凝固酶阴性葡萄球菌对万古霉素均敏感,利奈唑胺耐药率为1.8%(3/169);左氧氟沙星、环丙沙星、利福平和苯唑西林耐药率分别为36.6%(67/183)、31.6%(55/174)、17.2%(23/134)、63.9%(76/119);经验性用药方案中,包含革兰阴性覆盖的联合方案有效覆盖率最高。结论 本队列PJI 病原菌以革兰氏阳性球菌为主,这些病原菌对万古霉素、利奈唑胺等药物敏感,但对于喹诺酮类和利福平类的耐药水平较高。膝关节组真菌比例高于髋关节组,覆盖革兰阳性并兼顾革兰阴性杆菌如万古霉素+美罗培南为有效覆盖率最高的经验性用药方案。

     

    Abstract: Background Periprosthetic joint infection (PJI) represents one of the most catastrophic complications after joint replacement. Since bacterial culture results are often delayed, early treatment is largely dependent on empirical antibiotic therapy. However, substantial discrepancies in pathogen spectra and antimicrobial resistance exist across different regions and institutions, making external data unreliable for formulating local empiric regimens. Objective To characterize the etiological distribution and resistance patterns to commonly used empiric antibiotics in synovial fluid culture - positive PJI cases in Chinese PLA General Hospital. Methods A retrospective study was conducted on 214 patients with PJI who were treated in Chinese PLA General Hospital from May 2015 to December 2023. A total of 225 positive synovial fluid culture results were obtained (107 from hips and 118 from knees). Pathogen composition was summarized stratified by hip versus knee. Resistance rates to major antimicrobial agents and the effective coverage rates of commonly used empiric regimens were evaluated. Results Among the isolates, 180 were Gram-positive bacteria (80%), 27 were Gram-negative bacteria (12.0%), and 16 were fungi (7.1%). The Gram-positive isolates were predominantly Staphylococcus epidermidis (79, 35.1%) and Staphylococcus aureus (32, 14.2%). The Gram-negative isolates were mainly Escherichia coli (9, 4.0%) and Pseudomonas aeruginosa (7, 3.1%). The fungal isolates were primarily Candida parapsilosis (8, 3.6%) and Candida albicans (3, 1.3%). In the knee group (118 isolates), the most common pathogens were S. epidermidis (36, 30.5%), S. aureus (19, 16.1%), and C. parapsilosis (8, 6.8%). In the hip group (107 isolates), S. epidermidis (43, 40.2%), S. aureus (13, 12.1%), and E. coli (8, 7.5%) were the most frequent. The proportion of fungi was higher in the knee group than that in the hip group (12.7% vs 0.9%, P<001), whereas E. coli was more prevalent in the hip group than that in the knee group (7.5% vs 0.8%, P= 015). Resistance profiling showed that no vancomycin resistance was detected and the resistance rate to linezolid was 1.8% (3/169). The resistance rates to levofloxacin, ciprofloxacin, rifampicin and oxacillin were 36.6% (67/183), 31.6% (55/174), 17.2% (23/134) and 63.9% (76/119), respectively. Among empiric regimens, combination therapies that included Gram-negative coverage achieved the highest effective coverage rates. Conclusion In this cohort, Gram-positive cocci are the predominant pathogens in PJI and remain susceptible to vancomycin and linezolid; however, relatively high resistance to fluoroquinolones and rifampicin is observed. Fungal infections are more common in knee PJIs than in hip PJIs. Empiric regimens covering Gram-positive organisms while also providing Gram-negative bacillary coverage—such as vancomycin plus meropenem—yield the highest effective coverage rates.

     

/

返回文章
返回